2023
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activation
2020
CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerCyclin D1CDK 4/6 inhibitorsBaseline tumor tissueClass of drugsAdjuvant settingEndocrine therapyTherapy initiationFrontline therapyInhibitor therapyPFS intervalStudy treatmentPredictive markerDisease progressionClinical trialsOutcome dataTreatment selectionPathway biomarkersBiopsy materialAverage age 62Tumor tissuePatientsFinal analysisTop quartile
2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
2010
Metachronous Primary Melanoma and Lymphoma
McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaTumor RegistryYale-New Haven HospitalConnecticut Tumor RegistryEffect of treatmentStudy patientsCutaneous melanomaSurvival differencesPrimary melanomaLymphomaPatientsMelanomaViral inductionDiagnosisGenetic mutationsSurvivalRegistryLonger intervalsMalesGender comparisonsFurther researchImmunosuppressionMalignancyNeoplasmsHospital
1997
Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChildFemaleGallium RadioisotopesHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRadiotherapy, AdjuvantTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsNegative 67Ga scanPositive 67Ga scanTime of diagnosisManagement of patientsHodgkin's diseaseStage IIIStage IPredictive valueGallium scanGross residual diseaseEnd of therapyNegative predictive valueLow predictive valueModality therapyProgressive diseaseResidual diseasePositive scansRadiation therapyPatientsTherapyDiseaseScansTreatmentDiagnosisChemotherapy
1993
Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparison
Sperling N, Paparella M, Yoon T, Zelterman D. Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparison. The Laryngoscope 1993, 103: 277-285. PMID: 8441315, DOI: 10.1288/00005537-199303000-00007.Peer-Reviewed Original ResearchConceptsAsymptomatic endolymphatic hydropsEndolymphatic hydropsTemporal boneMeniere's diseaseCoexistent pathologic conditionsSeverity of hydropsDisease researchOtologic symptomsSymptomatic patientsHistopathologic comparisonPathological featuresClassic symptomsHistopathological studyHydropsEndolymphatic ductPathologic conditionsSymptomsPatientsDiseaseSignificant differencesSecond groupBoneFirst groupMembrane ruptureUnanswered questions
1991
Is Bias Inherent in HCFA-Sponsored Research?-Reply
Garrard J, Kane R, Makris L, Dunham T, Heston L, Cooper S, Ratner E, Zelterman D. Is Bias Inherent in HCFA-Sponsored Research?-Reply. JAMA 1991, 266: 64-64. DOI: 10.1001/jama.1991.03470010067022.Peer-Reviewed Original ResearchAge-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic Study
Ruah C, Schachern P, Zelterman D, Paparella M, Yoon T. Age-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic Study. JAMA Otolaryngology - Head & Neck Surgery 1991, 117: 627-634. PMID: 2036184, DOI: 10.1001/archotol.1991.01870180063013.Peer-Reviewed Original ResearchConceptsTympanic membraneAge-related morphologic changesFull-term infantsOtoscopic appearancePathologic evidenceWeeks' gestationOtologic diseaseTemporal boneOlder ageMorphologic changesElectron microscopic studyNormal changesGestationFirst yearMicroscopic studyPatientsInfantsVascularityYearsCellularityDisease